^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Microtubule inhibitor

    Related drugs:
    1d
    Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=88, Recruiting, Alliance for Clinical Trials in Oncology | Suspended --> Recruiting
    Enrollment open
    |
    dexamethasone • Blenrep (belantamab mafodotin-blmf) • iberdomide (CC-220)
    1d
    Prognostic value of the modified Glasgow Prognostic Score and Prognostic Nutritional Index in prostate cancer treated with cabazitaxel. (PubMed, Int J Clin Oncol)
    The mGPS and PNI are useful prognostic indicators for risk stratification to predict survival in patients with castration-resistant prostate cancer treated with cabazitaxel.
    Journal
    |
    CRP (C-reactive protein)
    |
    cabazitaxel
    1d
    AKT1 phosphorylates PRMT7 to promote GLUD1 methylation and gastric cancer progression. (PubMed, Cell Death Dis)
    In xenograft models, PRMT7 inhibitor SGC3027 combined with chemotherapeutic drugs docetaxel (DTX) synergistically suppresses tumor growth. Collectively, this study identifies the AKT1-PRMT7-GLUD1 axis as a key regulatory pathway in gastric cancer, and highlights its potential as a therapeutic target.
    Journal
    |
    AKT1 (V-akt murine thymoma viral oncogene homolog 1) • PRMT7 (Protein Arginine Methyltransferase 7)
    |
    docetaxel
    1d
    Impact of trastuzumab deruxtecan (T-DXd) and brain stereotactic radiosurgery on intracranial control and radionecrosis risk in HER2-positive or -low breast cancer brain metastases. (PubMed, Breast)
    Combining T-DXd with SRS demonstrated a favorable safety profile without increasing the risk of radionecrosis. Furthermore, this combination was associated with superior intracranial control, encompassing both local and distant outcomes, supporting the potential of T-DXd combined with SRS as an effective and well-tolerated approach for HER2-positive or -low BCBM.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki)
    1d
    Folate receptor alpha (FRα) expression in tubo-ovarian and endometrial tumors: a study of 923 cases. (PubMed, J Pathol Clin Res)
    Recently, the antibody-drug conjugate mirvetuximab soravtansine has been approved for treatment of advanced platinum-resistant high-grade serous carcinoma (HGSC)...In conclusion, these results confirm that FRα expression in HGSC and LGSC reaches similar values compared to published data, and is present in a minority of endometrial serous carcinomas. In other ovarian and endometrial tumors examined, FRα expression is absent or rare.
    Journal
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 expression
    |
    Elahere (mirvetuximab soravtansine-gynx)
    1d
    Immunohistochemical biomarkers to predict adjuvant chemotherapy response in patients with early breast cancer in the MATADOR trial (BOOG 2005-02). (PubMed, Breast)
    Patients with TN EZH2low tumours benefit more from ddAC, while EZH2high have a better outcome after TAC. High tubulin expression may predict docetaxel benefit if adjusted for sTILs. Further research with more patients is needed to find the best use of these biomarkers.
    Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • TUBB3 (Tubulin beta 3 class III) • GSTP1 (Glutathione S-transferase pi 1) • MAPT (Microtubule Associated Protein Tau)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    docetaxel • doxorubicin hydrochloride • cyclophosphamide
    1d
    Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer (clinicaltrials.gov)
    P2, N=31, Not yet recruiting, Fudan University
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1)
    |
    MSI-H/dMMR • BRAF mutation • RAS wild-type
    |
    Erbitux (cetuximab) • Meiyouheng (becotatug vedotin) • becotarug (JMT101)
    2d
    KEYNOTE-869: A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer (clinicaltrials.gov)
    P1/2, N=348, Terminated, Astellas Pharma Global Development, Inc. | Trial completion date: Sep 2026 --> Feb 2026 | Active, not recruiting --> Terminated; Sponsor stopped the study after meeting enrollment targets and primary objectives, and after collecting sufficient data for planned regulatory filings. The decision was not due to safety concerns, futility, or any regulatory request.
    Trial completion date • Trial termination
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • Padcev (enfortumab vedotin-ejfv)
    2d
    A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, West China Hospital
    New trial • Real-world evidence • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Tyvyt (sintilimab) • Aidixi (disitamab vedotin)
    2d
    An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=65, Active, not recruiting, AbbVie | Trial completion date: Dec 2025 --> May 2026 | Trial primary completion date: Dec 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    PTK7 (Protein Tyrosine Kinase 7)
    |
    cofetuzumab pelidotin (ABBV-647)
    3d
    FASN: Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer (clinicaltrials.gov)
    P2, N=50, Recruiting, Wake Forest University Health Sciences | Trial completion date: Apr 2030 --> Mar 2028
    Trial completion date
    |
    docetaxel • cabazitaxel • omeprazole